Jonathan Mink, MD, PHD
NPI: 1689680217
Total Payments
$92,029
2024 Payments
$5,597
Companies
12
Transactions
72
Payment Breakdown by Category
Consulting$37,334 (40.6%)
Research$31,000 (33.7%)
Other$10,686 (11.6%)
Travel$9,161 (10.0%)
Education$3,422 (3.7%)
Food & Beverage$425.80 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,334 | 26 | 40.6% |
| Unspecified | $31,000 | 21 | 33.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,686 | 8 | 11.6% |
| Travel and Lodging | $9,161 | 6 | 10.0% |
| Education | $3,422 | 2 | 3.7% |
| Food and Beverage | $425.80 | 9 | 0.5% |
Payments by Type
General
$61,029
51 transactions
Research
$31,000
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PTC Therapeutics, Inc. | $37,600 | 27 | $0 (2024) |
| Amicus Therapeutics, Inc. | $24,935 | 12 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $9,012 | 14 | $0 (2022) |
| BioMarin Pharmaceutical Inc. | $7,508 | 4 | $0 (2022) |
| Applied Therapeutics, inc. | $3,600 | 4 | $0 (2023) |
| Biogen, Inc. | $2,880 | 1 | $0 (2021) |
| Sumitomo Pharma Co., Ltd. | $2,800 | 2 | $0 (2024) |
| MDD US Operations, LLC | $2,000 | 1 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $712.50 | 1 | $0 (2021) |
| Sumitomo Dainippon Pharma Co., Ltd. | $450.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,597 | 9 | PTC Therapeutics, Inc. ($4,100) |
| 2023 | $16,235 | 11 | PTC Therapeutics, Inc. ($11,400) |
| 2022 | $27,766 | 15 | PTC Therapeutics, Inc. ($15,500) |
| 2021 | $11,033 | 10 | Biogen, Inc. ($2,880) |
| 2020 | $8,100 | 7 | Amicus Therapeutics, Inc. ($4,300) |
| 2019 | $15,904 | 12 | Amicus Therapeutics, Inc. ($13,235) |
| 2018 | $3,672 | 5 | Teva Pharmaceuticals USA, Inc. ($3,222) |
| 2017 | $3,722 | 3 | BioMarin Pharmaceutical Inc. ($3,422) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $22.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/23/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $22.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/12/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $24.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/11/2024 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | ||||||
| 06/19/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $27.11 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/29/2024 | Sumitomo Pharma Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 02/20/2024 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $400.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 01/25/2024 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $2,400.00 | Research |
| Study: A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | ||||||
| 01/25/2024 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | ||||||
| 10/05/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 09/08/2023 | Sumitomo Pharma Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 09/01/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 08/03/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $2,300.00 | Research |
| Study: AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | ||||||
| 05/01/2023 | Applied Therapeutics, inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 04/28/2023 | MDD US Operations, LLC | GOCOVRI (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 04/27/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 04/21/2023 | Spark Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $435.00 | General |
| 04/06/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 03/16/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | ||||||
| 03/02/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $800.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 12/08/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 11/09/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | ||||||
| 10/27/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 10/06/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | ||||||
| 09/22/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $2,800.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | PTC Therapeutics, Inc. | $16,100 | 10 |
| AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | PTC Therapeutics, Inc. | $5,000 | 4 |
| EVALUATION OF THE EFFICACY AND SAFETY OF PTC299 IN HOSPITALIZED SUBJECTS WITH COVID-19 (FITE19) | PTC Therapeutics, Inc. | $2,800 | 2 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | PTC Therapeutics, Inc. | $2,500 | 2 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | PTC Therapeutics, Inc. | $2,400 | 1 |
| AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | PTC Therapeutics, Inc. | $2,200 | 2 |
About Jonathan Mink, MD, PHD
Jonathan Mink, MD, PHD is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689680217.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jonathan Mink, MD, PHD has received a total of $92,029 in payments from pharmaceutical and medical device companies, with $5,597 received in 2024. These payments were reported across 72 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($37,334).
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Rochester, NY
- Active Since 08/01/2006
- Last Updated 07/05/2023
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1689680217
Products in Payments
- AUSTEDO (Drug) $8,698
- Brineura (Biological) $4,086
- BMN 190 (Biological) $3,422
- GOCOVRI (Drug) $2,000
- Impella (Device) $96.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Rochester
Erika Augustine, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $52,760
Neurology with Special Qualifications in Child Neurology $52,760
Dr. Yuliya Snyder, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $8,586
Neurology with Special Qualifications in Child Neurology $8,586
Jennifer Nguyen, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $4,347
Neurology with Special Qualifications in Child Neurology $4,347
Duygu Selcen, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $2,323
Neurology with Special Qualifications in Child Neurology $2,323
Dr. Evelyn Berman, M.d. M.s, M.D. M.S
Neurology with Special Qualifications in Child Neurology — Payments: $1,711
Neurology with Special Qualifications in Child Neurology $1,711
John Bodensteiner, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $1,565
Neurology with Special Qualifications in Child Neurology $1,565